Astrazeneca (AZN) Work In Process (2015 - 2025)

Astrazeneca's Work In Process history runs 11 years deep, the most recent figure standing at $2.8 billion for Q4 2025.

• In Q4 2025, Work In Process rose 21.69% year-over-year to $2.8 billion; the TTM figure through Dec 2025 stood at $2.8 billion (up 21.69% YoY), while the FY2025 annual figure was $2.8 billion, up 21.69% from the prior year.
• Work In Process was $2.8 billion for Q4 2025 at Astrazeneca, up from $2.3 billion in the prior quarter.
• In the past five years, Work In Process ranged from a high of $5.2 billion in Q4 2021 to a low of $1.9 billion in Q4 2022.
• Historically, Work In Process has averaged $2.9 billion across 5 years, with a median of $2.3 billion in 2023.
• The sharpest annual moves came in 2021 and 2022: Work In Process jumped 291.89% in 2021, then plunged 64.26% in 2022.
• A 5-year view of Work In Process shows it stood at $5.2 billion in 2021, then slumped by 64.26% to $1.9 billion in 2022, then increased by 24.73% to $2.3 billion in 2023, then declined by 1.85% to $2.3 billion in 2024, then advanced by 21.69% to $2.8 billion in 2025.
• The last three Work In Process figures came in at $2.8 billion (Q4 2025), $2.3 billion (Q4 2024), and $2.3 billion (Q4 2023), per Business Quant data.